JW Shinyak Corp banner
J

JW Shinyak Corp
KOSDAQ:067290

Watchlist Manager
JW Shinyak Corp
KOSDAQ:067290
Watchlist
Price: 2 100 KRW 3.7% Market Closed
Market Cap: ₩117.7B

P/OCF

19.5
Current
5%
More Expensive
vs 3-y average of 18.6

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
19.5
=
Market Cap
₩121.3B
/
Operating Cash Flow
₩6B

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
19.5
=
Market Cap
₩121.3B
/
Operating Cash Flow
₩6B

Valuation Scenarios

JW Shinyak Corp is trading above its 3-year average

If P/OCF returns to its 3-Year Average (18.6), the stock would be worth ₩2 005 (5% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-54%
Maximum Upside
+19%
Average Downside
15%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple 19.5 ₩2 100
0%
3-Year Average 18.6 ₩2 005
-5%
5-Year Average 23.1 ₩2 489.4
+19%
Industry Average 15.3 ₩1 652.81
-21%
Country Average 9 ₩969.67
-54%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close
Market Cap P/OCF P/E
KR
JW Shinyak Corp
KOSDAQ:067290
117.3B KRW 19.5 8.6
US
Eli Lilly and Co
NYSE:LLY
835.2B USD 49.7 40.5
US
Johnson & Johnson
NYSE:JNJ
547.8B USD 22.3 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 13.7 20.1
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 19.7 28
CH
Novartis AG
SIX:NOVN
223.1B CHF 14.3 19.5
US
Merck & Co Inc
NYSE:MRK
276.9B USD 16.8 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 907.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 9.8 11.4
US
Pfizer Inc
NYSE:PFE
153.5B USD 13.1 19.8
US
Bristol-Myers Squibb Co
NYSE:BMY
118.2B USD 8.3 16.8
P/E Multiple
Earnings Growth PEG
KR
J
JW Shinyak Corp
KOSDAQ:067290
Average P/E: 20.6
8.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.5
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.8
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

Higher than 73% of companies in Korea
Percentile
73rd
Based on 1 012 companies
73rd percentile
19.5
Low
0.2 — 4.2
Typical Range
4.2 — 16.6
High
16.6 —
Distribution Statistics
Korea
Min 0.2
30th Percentile 4.2
Median 9
70th Percentile 16.6
Max 2 215 132.4

JW Shinyak Corp
Glance View

Market Cap
117.7B KRW
Industry
Pharmaceuticals

JW SHINYAK Corp. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Seoul, Seoul. The company went IPO on 2003-02-11. The Company’s main products portfolio consists of antibiotics, anesthetics, respiratory remedies, urology remedies, cardiovascular remedies, allergy remedies, digestive remedies, anti-inflammatory drugs, antivirals as well as acne remedies, among others. In addition, it also involves in the provision of cosmetics, such as creams, cleansers, toners, essences, lotions and others.

Intrinsic Value
1 703.41 KRW
Overvaluation 19%
Intrinsic Value
Price ₩2 100
J
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett